Public trial registry of the CCC-Munich

Trial CMEK162X2201

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
CMEK162X2201
World
Full title
:

A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma,harboring BRAFV600 or NRAS mutations

World
EudraCT number
:
World
Responsible organization
:
KUM - Klinik und Poliklinik für Dermatologie und Allergologie - Dermato-Onkologie Lmu
Indications
Classification Code Description
ICD-10-GM C43.- Bösartiges Melanom der Haut
Trial design
World
Trial type
:
Interventional
Status
World
Status
:
Trial finished
Votes
World
Institutional review board - vote
:
Positive
World
PEI - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / 2017-02-06
Participants
Function Prename Surname Organization
World Principal Investigator Carola Berking KUM - Klinik und Poliklinik für Dermatologie und Allergologie Magnifier
World Responsible contact Carola Berking KUM - Klinik und Poliklinik für Dermatologie und Allergologie Magnifier
World Sponsor Novartis Magnifier